EHA / 14th Congress / Program overview per day / Sunday Program

Simultaneous Session

Plenary Sessions Hematology-in-Focus sessions Clinical Trial Update Simultaneous Sessions

SIMULTANEOUS SESSION

08:00 – 09:15, Hall 2

INDOLENT NON-HODGKIN CLINICAL

Chairs: S Montoto (St. Bartholomew's Hospital, London, United Kingdom)

08:00 – 08:15

1040	HAIRY CELL LEUKEMIAS (HCL) WITH UNMUTATED IGHV GENES DEFINE THE MINOR SUBSET REFRACTORY TO SINGLE AGENT CLADRIBINE AND WITH MORE AGGRESSIVE BEHAVIOR F. Forconi, E. Cencini, F. Zaja, T. Intermesoli, C. Stelitano, L. Rigacci,F. Gherlinzoni, R. Cantaffa, A. Baraldi, A. Gallamini, A. Zaccaria, E. Sozzi, A. Pulsoni, M. Gobbi, M. Tassi, D. Raspadori, A. Rinaldi, L. Leoncini, E. Sabattini, S. Pileri, F. Bertoni, F. Lauria (University of Siena, Siena, Italy

1040

HAIRY CELL LEUKEMIAS (HCL) WITH UNMUTATED IGHV GENES DEFINE THE MINOR SUBSET REFRACTORY TO SINGLE AGENT CLADRIBINE AND WITH MORE AGGRESSIVE BEHAVIOR
F. Forconi, E. Cencini, F. Zaja, T. Intermesoli, C. Stelitano, L. Rigacci,F. Gherlinzoni, R. Cantaffa, A. Baraldi, A. Gallamini, A. Zaccaria, E. Sozzi, A. Pulsoni, M. Gobbi, M. Tassi, D. Raspadori, A. Rinaldi, L. Leoncini, E. Sabattini, S. Pileri, F. Bertoni, F. Lauria (University of Siena, Siena, Italy

08:15 – 08:30

1041	BRIEF CHEMOIMMUNOTHERAPY RITUXIMAB (R)-FND +/- RMAINTENANCE IS EFFECTIVE AND SAFE IN NEWLY DIAGNOSED FOLLICULAR LYMPHOMA ELDERLY PATIENTS: AN INTERGRUPPO ITALIANO LINFOMI (IIL) RANDOMIZED TRIAL U. Vitolo, M. Ladetto, C. Boccomini, E. Gamba, I. Alvarez, L. Baldini, A. Chiappella, P. Corradini, A. De Renzo, F. Di Raimondo, A. Evangelista, A. Gallamini, A. Guarini, B. Mantoan, M. Martelli, L. Orsucci, G. Parvis, M. Petrini, A. Pinto, S. Pozzi, A. Pulsoni, L. Rigacci, E. Russo, C. Tarella, A. Tucci, F. Zaja, E. Gallo (On the behalf of Intergruppo Italiano Linfomi, Hematology, ASO San G. Battista, Turin, Italy)

1041

BRIEF CHEMOIMMUNOTHERAPY RITUXIMAB (R)-FND +/- RMAINTENANCE IS EFFECTIVE AND SAFE IN NEWLY DIAGNOSED FOLLICULAR LYMPHOMA ELDERLY PATIENTS: AN INTERGRUPPO ITALIANO LINFOMI (IIL) RANDOMIZED TRIAL
U. Vitolo, M. Ladetto, C. Boccomini, E. Gamba, I. Alvarez, L. Baldini, A. Chiappella, P. Corradini, A. De Renzo, F. Di Raimondo, A. Evangelista, A. Gallamini, A. Guarini, B. Mantoan, M. Martelli, L. Orsucci, G. Parvis, M. Petrini, A. Pinto, S. Pozzi, A. Pulsoni, L. Rigacci, E. Russo, C. Tarella, A. Tucci, F. Zaja, E. Gallo (On the behalf of Intergruppo Italiano Linfomi, Hematology, ASO San G. Battista, Turin, Italy)

08:30 – 08:45

1042	90YTTRIUM IBRITUMOMAB TIUXETAN (ZEVALIN) COMBINED WITH BEAM (Z -BEAM) CONDITIONING REGIMEN PLUS AUTOLOGOUS STEM CELL TRANSPLANTATION IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA. A GELA PHASE II PROSPECTIVE STUDY C. Gisselbrecht, D. Decaudin, N. Mounier, H. Tilly, V. Ribrag, C. Sebban, N. Milpied, F. Morschhauser, B. Coiffier, S. Le Gouill, P. Lederlin, R. Delarue, G. Laurent, A. Bosly (Institut d'Hématologie, Paris, France)

1042

90YTTRIUM IBRITUMOMAB TIUXETAN (ZEVALIN) COMBINED WITH BEAM (Z -BEAM) CONDITIONING REGIMEN PLUS AUTOLOGOUS STEM CELL TRANSPLANTATION IN RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA. A GELA PHASE II PROSPECTIVE STUDY
C. Gisselbrecht, D. Decaudin, N. Mounier, H. Tilly, V. Ribrag, C. Sebban, N. Milpied, F. Morschhauser, B. Coiffier, S. Le Gouill, P. Lederlin, R. Delarue, G. Laurent, A. Bosly (Institut d'Hématologie, Paris, France)

08:45 – 09:00

1043	RESULTS OF A PROSPECTIVE RANDOMISED TRIAL COMPARING CHLORAMBUCIL, MITOXANTRONE AND DEXAMETHASONE (CMD) VERSUS FLUDARABINE, MITOXANTRONE AND DEXAMETHASONE(FMD) AS PRIMARY THERAPY FOR ADVANCED STAGE FOLLICULAR LYMPHOMA (REAL GRADES I-III, STAGE III/IV). A REPORT FROM THE UK CENTRAL AND SOUTHERN LYMPH R.J. Lush, A. Haynes, A. McMillan, A. Jack, W. Qian, I. Jakupovic, P. Smith, A. Prentice (Cheltenham General Hospital, Cheltenham, United Kingdom)

1043

RESULTS OF A PROSPECTIVE RANDOMISED TRIAL COMPARING CHLORAMBUCIL, MITOXANTRONE AND DEXAMETHASONE (CMD) VERSUS FLUDARABINE, MITOXANTRONE AND DEXAMETHASONE(FMD) AS PRIMARY THERAPY FOR ADVANCED STAGE FOLLICULAR LYMPHOMA (REAL GRADES I-III, STAGE III/IV). A REPORT FROM THE UK CENTRAL AND SOUTHERN LYMPH
R.J. Lush, A. Haynes, A. McMillan, A. Jack, W. Qian, I. Jakupovic, P. Smith, A. Prentice (Cheltenham General Hospital, Cheltenham, United Kingdom)

09:00 – 09:15

1044	SINGLE AGENT BORTEZOMIB IS ACTIVE IN RELAPSED/REFRACTORY MALT LYMPHOMAS. FINAL RESULTS OF AN INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG) PHASE II STUDY A. Conconi, G. Martinelli, A. Lopez-Guillermo, P.L. Zinzani, A. Ferreri, L. Rigacci, L. Devizzi, U. Vitolo, S. Luminari, M. Martelli, F. Cavalli, E. Zucca (International Extranodal Lymphoma Study Group (IELSG), Bellinzona, Switzerland)

1044

SINGLE AGENT BORTEZOMIB IS ACTIVE IN RELAPSED/REFRACTORY MALT LYMPHOMAS. FINAL RESULTS OF AN INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP (IELSG) PHASE II STUDY
A. Conconi, G. Martinelli, A. Lopez-Guillermo, P.L. Zinzani, A. Ferreri, L. Rigacci, L. Devizzi, U. Vitolo, S. Luminari, M. Martelli, F. Cavalli, E. Zucca (International Extranodal Lymphoma Study Group (IELSG), Bellinzona, Switzerland)

SIMULTANEOUS SESSION

08:00 – 09:15, Hall 3

MYELOPROLIFERATIVE DISORDERS - BIOLOGY

Chairs: A Vannucchi (University of Florence, Florence, Italy) R Skoda (Basel University Hospital, Basel, Switzerland)

08:00 – 08:15

1045	A GERMLINE JAK2 SNP IS ASSOCIATED WITH PREDISPOSITION TO THE DEVELOPMENT OF JAK2 V617F-POSITIVE MYELOPROLIFERATIVE NEOPLASMS O.M. Kilpivaara, S. Mukherjee, M Schram, M. Wadleigh, A. Mullally, L Ebert, €A. Bass, S. Marubayashi, A. Heguy, G. Garcia-Manero, H. Kantarjian, K. Offit, M. Stone, D. Gilliland, J. Klein, L. Levine (Memorial Sloan-Kettering Cancer Institute, New York, USA)

08:15 – 08:30

1046	CHROMATIN MODIFICATION- A NUCLEAR ROLE FOR JAK2 A. Dawson, A. Bannister, B. Gottgens, T. Bartke, S. Foster, T. Kouzarides, A. Green (Cambridge Institute for Medical research, Cambridge, United Kingdom)

08:30 – 08:45

1047	TET2 MUTATION PREVALENCE AND CLINICAL CORRELATES IN A SPECTRUM OF MYELOID NEOPLASMS: A SINGLE INSTITUTION STUDY OF 337 PATIENTS D. Pardanani, T. Lasho, K. Lim, O. Abdel-Wahab, J. Patel, N. Gangat, C. Finke, S. Schwager, A. Mullally, C. Li, C. Hanson, R. Mesa, A. Pardanani, G. Gilliland, R. Levine, A. Tefferi (Mayo Clinic, Rochester, USA)

08:45 – 09:00

1048	MULTIPLE JAK2 V617F MUTATIONS ARE PRESENT IN MOST PATIENTS WITH ESSENTIAL THROMBOCYTHAEMIA: A NEW DISEASE PARADIGM J. Lambert, D.C. Linch, R.E. Gale (University College London Cancer Institute, London, United Kingdom)

09:00 – 09:15

1049	TWO ROUTES TO LEUKAEMIC TRANSFORMATION FOLLOWING A JAK2 MUTATION-POSITIVE MYELOPROLIFERATIVE NEOPLASM P.A. Beer, F. Delhommeau, J.P. LeCouédic, D. Bareford, R. Ku_ec, M.F. McMullin, C. Harrison, A. Vannucchi, W. Vainchenker, A.R. Green (Cambridge Institute for Medical Research, Cambridge, United Kingdom)

SIMULTANEOUS SESSION

08:00 – 09:15, Hall 15.2

NEW ANTITHROMBOTIC AGENTS

Chair: G Agnelli (Ospedale S. Maria della Misericordia, Università di Perugia, Perugia, Italy)

UNMET CLINICAL NEEDS IN THE PREVENTION AND TREATMENT OF THROMBOEMBOLIC DISEASES
G Agnelli (Ospedale S. Maria della Misericordia, Università di Perugia, Perugia, Italy)
UPDATE ON THE PREVENTION AND TREATMENT OF VENOUS THROMBOEMBOLISM
M Huisman (Leiden University Medical Center, Leiden, The Netherlands)
UPDATE ON THE PREVENTION AND TREATMENT OF ARTERIAL THROMBOEMBOLISM
M Cattaneo (Ospedale San Paolo, Università di Milano, Milan, Italy)

SIMULTANEOUS SESSION

08:00 – 09:15, Hall 2.1

CHRONIC MYELOID LEUKEMIA - BIOLOGY II

Chairs: B Simonsson (University Hospital, Uppsala, Sweden)
R Hehlmann (Klinikum Mannheim der Universität Heidelberg,
Mannheim, Germany)

08:00 – 08:15

1050	GENOME-WIDE SCREENING OF CHRONIC MYELOID LEUKEMIA PATIENTS BY SNP ARRAYS: ALTERATIONS ASSOCIATED WITH DISEASE PROGRESSION S. Colarossi, A. Gnani, S. Soverini, F. Castagnetti, G. Marzocchi, S. Luatti, A. Astolfi, S. Formica, I. Iacobucci, M. Amabile, A. Poerio, G. Rosti, A. Pession, N. Testoni, M. Baccarani, G. Martinelli (Institute of Hematology and Medical Oncology Seràgnoli, Bologna, Italy)

1050

GENOME-WIDE SCREENING OF CHRONIC MYELOID LEUKEMIA PATIENTS BY SNP ARRAYS: ALTERATIONS ASSOCIATED WITH DISEASE PROGRESSION
S. Colarossi, A. Gnani, S. Soverini, F. Castagnetti, G. Marzocchi, S. Luatti, A. Astolfi, S. Formica, I. Iacobucci, M. Amabile, A. Poerio, G. Rosti, A. Pession, N. Testoni, M. Baccarani, G. Martinelli (Institute of Hematology and Medical Oncology Seràgnoli, Bologna, Italy)

08:15 – 08:30

1051	ICSBP DEFICIENCY IN CML CONFERS DIRECT BCR/ABLINDEPENDENTIMATINIB RESISTANCE BUT RESTRICTS BCR/ABL KINASE POINT MUTATION DEVELOPMENT A. Chaturvedi, K. Schmidt, A. Neubauer, A. Burchert (Philipps University, Marburg, Marburg, Germany)

08:30 – 08:45

1052	OMACETAXINE CYTOTOXIC ACTIVITY IN CHRONIC MYELOID LEUKAEMIA STEM CELLS E.K. Allan, H.G. Jorgensen, S. Michaels, T.L. Holyoake (Scottish National Blood Transfusion Service, Glasgow, United Kingdom)

08:45 – 09:00

1053	BCR-ABL PEPTIDE VACCINATION IN HEALTHY SUBJECTS:IMMUNOLOGICAL RESPONSES ARE EQUIVALENT TO THOSE INCHRONIC MYELOID LEUKAEMIA PATIENTS J.M. Rojas, K. Knight, S. Watmough, J. Bell, L.H. Wang, T. Callaghan, R.E. Clark (University of Liverpool, Liverpool, United Kingdom)

09:00 – 09:15

1054	BCR-ABL ENHANCES DIFFERENTIATION OF LONG-TERM REPOPULATING HEMATOPOIETIC STEM CELLS M. Schemionek, C. Elling, N. Bäumer, A. Hamilton, T. Spieker, J. Göthert, M. Stehling, C. Huettner, D.G. Tenen, L. Tickenbrock, W.E. Berdel, H.L. Serve, T.L. Holyoake, C. Müller-Tidow (University of Muenster, Münster, Germany), S. Koschmieder

SIMULTANEOUS SESSION

08:00 – 09:15, Hall 7

BLEEDING DISORDERS, PLATELETS AND THROMBOCYTOPENIA

Chairs: A Falanga (Ospedali Riuniti, Bergamo, Italy

08:00 – 08:15

1055	ESTABLISHMENT OF A EUROPEAN NETWORK OF RARE BLEEDING DISORDERS (EN-RBD DATABASE): PRELIMINARY RESULTS ON 190 PATIENTS R. Palla, M. Menegatti, S.M. Siboni, M. Benedik-Dolnicar, C. Bidlingmaier,T. Celkan, P. Giangrande, R. Gilmore, J. Ingerslev, K. Peerlink, H. Pergantou,F. Suzan, M. Spreafico, R. Waha, P. Lanzi, F. Peyvandi (Hemophilia & thrombosis Centre, Dpt Internal Medicine, University of Milan, Milan, Italy)

1055

ESTABLISHMENT OF A EUROPEAN NETWORK OF RARE BLEEDING DISORDERS (EN-RBD DATABASE): PRELIMINARY RESULTS ON 190 PATIENTS
R. Palla, M. Menegatti, S.M. Siboni, M. Benedik-Dolnicar, C. Bidlingmaier,T. Celkan, P. Giangrande, R. Gilmore, J. Ingerslev, K. Peerlink, H. Pergantou,F. Suzan, M. Spreafico, R. Waha, P. Lanzi, F. Peyvandi (Hemophilia & thrombosis Centre, Dpt Internal Medicine, University of Milan, Milan, Italy)

08:15 – 08:30

1056	RETROSPECTIVE EVALUATION OF DYSFIBRINOGENEMIC PATIENTS AT A SINGLE CENTER: CLINICAL FEATURES AND LABORATORY FINDINGS C. Santoro, A.P. Leporace, F. Biondo, M. Platè, R. Asselta, F. Peyvandi, M. Menegatti, P. Pignoloni, S. Duga, R. Foà, M.G. Mazzucconi (Hematology, Rome, Italy)

08:30 – 08:45

1057	THE CONFORMATIONAL CHANGES OF THE VON WILLEBRAND FACTOR (VWF) TESTED BY NANOBODY AU/VWF-A11 IN A COHORT OF 86 PATIENTS WITH DIFFERENT TYPES OF VON WILLEBRAND DISEASE: AN ADDITIONAL TOOL TO LOCALYZE MOLECULAR DEFECTS OF VWF A.B. Federici, E. Groot, M. Punzo, P.J. Lenting, F. Rezzonico, L. Baronciani, P.G. De Groot (University of Milan, Milan, Italy)

08:45 – 09:00

1058	ASSOCIATION OF HEALTH-RELATED QUALITY OF LIFE (HRQOL), BLEEDING, AND PLATELET LEVELS IN CHRONIC IDIOPATHICTHROMBOCYTOPENIC PURPURA (ITP): RESULTS FROM RAISE AND EXTEND J. Bussel, K.M. Grotzinger, M. Duh, J. Signorovitch, N.L. Stone, A. Brainsky (Weill Cornell Medical College, New York, USA)

09:00 – 09:15

1059	EFFICACY AND SAFETY OF ROMIPLOSTIM VERSUS MEDICAL STANDARD OF CARE AS CHRONIC THERAPY FOR NONSPLENECTOMIZED PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP) J. Rummel, R. Boccia, B.G. Macik, I. Pabinger, D. Selleslag, L. Gehl, X. Wang, D.P. Berger, D.J. Kuter (Klinikum der Justus-Liebig-Universität, Giessen, Germany)

SIMULTANEOUS SESSION

08:00 – 09:15, Hall 14.2

ACUTE LYMPHOBLASTIC LEUKEMIA - BIOLOGY II

Chairs: A Biondi (University of Milano-Bicocca, Monza, Italy)
I Lahortiga (KULeuven, Leuven, Belgium)

08:00 – 08:15

1060	PAX5 GENE IS FREQUENTLY REARRANGED IN A LARGE COHORT OF BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: ON BEHALF OF GIMEMA AL & MDS WP I. Iacobucci, A. Lonetti, C.T. Storlazzi, A. Ferrari, D. Cilloni, F. Messa, S. Chiaretti, C. Papayannidis, M. Messina, A. Vitale, E. Ottaviani, S. Soverini, A. Astolfi, L. Impera, F. Arruga, P.P. Piccaluga, S. Paolini, M. Baccarani, G. Saglio, F. Pane, R. Foà, G. Martinelli (Department of Hematology/Oncology “Seràgnoli”, Bologna, Italy)

1060

PAX5 GENE IS FREQUENTLY REARRANGED IN A LARGE COHORT OF BCR-ABL1-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: ON BEHALF OF GIMEMA AL & MDS WP
I. Iacobucci, A. Lonetti, C.T. Storlazzi, A. Ferrari, D. Cilloni, F. Messa, S. Chiaretti, C. Papayannidis, M. Messina, A. Vitale, E. Ottaviani, S. Soverini, A. Astolfi, L. Impera, F. Arruga, P.P. Piccaluga, S. Paolini, M. Baccarani, G. Saglio, F. Pane, R. Foà, G. Martinelli (Department of Hematology/Oncology “Seràgnoli”, Bologna, Italy)

08:15 – 08:30

1061	MICRORNA SIGNATURES IN GENETIC SUBTYPES OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA J.C. Van der Meulen, P. Van Vlierberghe, P. Mestdagh, J. Vandesompele, B. Poppe, N. Van Roy, T. Taghon, J. Plum, B. Cauwelier, D.L.D. Selleslag, P. Heimann, P. Vandenberghe, N. Dastugue, E. Delabesse, C. Gervais, M.-J. Gregoire, M.-J. Mozzicconacci, C. Lefebvre, J.P.P. Meijerink, J. Buijs-Gladdines, B. De Moerloose, Y. Benoit, A. De Paepe, F. Speleman (Ghent University Hospital, Ghent, Belgium)

1061

MICRORNA SIGNATURES IN GENETIC SUBTYPES OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
J.C. Van der Meulen, P. Van Vlierberghe, P. Mestdagh, J. Vandesompele, B. Poppe, N. Van Roy, T. Taghon, J. Plum, B. Cauwelier, D.L.D. Selleslag, P. Heimann, P. Vandenberghe, N. Dastugue, E. Delabesse, C. Gervais, M.-J. Gregoire, M.-J. Mozzicconacci, C. Lefebvre, J.P.P. Meijerink, J. Buijs-Gladdines, B. De Moerloose, Y. Benoit, A. De Paepe, F. Speleman (Ghent University Hospital, Ghent, Belgium)

08:30 – 08:45

1062	WILMS' TUMOR 1 GENE MUTATIONS IN ACUTE T-LYMPHOBLASTIC LEUKEMIA R. Ben Abdelali, A. Renneville, V. Asnafi, J.-B. Micol, O. Nibourel, S. Lenoir, S. Geffroy, M. Cheok, H. Dombret, E.A. Macintyre, C. Preudhomme (Necker Hospital, Paris, France)

08:45 – 09:00

1063	ANALYSIS OF GENOMIC BREAKPOINTS INDICATES THAT BCR-ABL IN ACUTE LYMPHOBLASTIC LEUKAEMIA MAY ARISE IN A COMMITTED LYMPHOID PROGENITOR CELL IN A SUBSET OF CASES J.C. Score, M.J. Calasanz, F. Pane, O. Ottmann, R.-F. Yeh, J. Wiemels, F.H. Grand, N.C.P. Cross (WRGL, University of Southampton, Salisbury, United Kingdom)

09:00 – 09:15

1064	IKZF (IKAROS) DELETIONS IN BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) ARE ASSOCIATED WITH AN IMPAIRED B-CELL DIFFERENTIATION AND POOR OUTCOME I. Iacobucci, C.T. Storlazzi, A. Lonetti, A. Ferrari, E. Ottaviani, S. Chiaretti, M. Messina, D. Cilloni, C. Baldazzi, C. Papayannidis, F. Messa, A. Astolfi, S. Durante, A. Vitale, F. Arruga, F. Pane, P.P. Piccaluga, S. Colarossi, S. Soverini, M. Vignetti, S. Paolini, G. Saglio, M. Baccarani, R. Foà, G. Martinelli (Department of Hematology/Oncology “Seràgnoli”, Bologna, Italy)

1064

IKZF (IKAROS) DELETIONS IN BCR-ABL1 POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) ARE ASSOCIATED WITH AN IMPAIRED B-CELL DIFFERENTIATION AND POOR OUTCOME
I. Iacobucci, C.T. Storlazzi, A. Lonetti, A. Ferrari, E. Ottaviani, S. Chiaretti, M. Messina, D. Cilloni, C. Baldazzi, C. Papayannidis, F. Messa, A. Astolfi, S. Durante, A. Vitale, F. Arruga, F. Pane, P.P. Piccaluga, S. Colarossi, S. Soverini, M. Vignetti, S. Paolini, G. Saglio, M. Baccarani, R. Foà, G. Martinelli (Department of Hematology/Oncology “Seràgnoli”, Bologna, Italy)

SIMULTANEOUS SESSION

08:00 – 09:15, Hall 4/5

ACUTE MYELOID LEUKEMIA – CLINICAL

Chairs: R Schlenk (University of Ulm, Ulm, Germany)

08:00 – 08:15

1065	A MULTICENTER PHASE I-II STUDY OF TOSEDOSTAT IN THE TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORYACUTE MYELOID LEUKAEMIA G. Ossenkoppele, W. Hooftman, S. Zweegman, E. Davies, G. Morgan, C. Mueller-Tidow, U. Krug, U. Duhrsen, A. Burnett, C. Jenkins, P. Zachee, D. Dierickx, B. Lowenberg, P. Sonneveld, L. Hooftman, A. Richardson (VUMC, Amsterdam, The Netherlands)

08:15 – 08:30

1066	5' AZACITIDINE IN COMBINATION WITH VALPROIC ACID INDUCES COMPLETE REMISSIONS IN PATIENTS WITH HIGH RISK ACUTE MYELOID LEUKAEMIA BUT DOES NOT ERADICATE CLONAL LEUKAEMIC STEM/PROGENITOR CELLS C. Craddock, N. Goardon, M. Griffiths, S. Siddique, J. Cavenagh, P. Vyas (Queen Elizabeth Hospital, Birmingham, United Kingdom)

08:30 – 08:45

1067	NOVEL PROGNOSTICS SUBGROUPS IN CHILDHOOD 11Q23/MLLREARRANGED ACUTE MYELOID LEUKEMIA AS DEFINED BY TRANSLOCATION PARTNERS: A RETROSPECTIVE INTERNATIONAL STUDY B.V. Balgobind, S.C. Raimondi, J. Harbott, M. Zimmermann, T. Alonzo, A. Auvrignon, H.B. Beverloo, M. Chang, U. Creutzig, M.N. Dworzak, E. Forestier, B. Gibson, H. Hasle, C. Harrison, N.A. Heerema, G.J.L. Kaspers, A. Leszl, N. Litvinko, L. Lo Nigro, A. Morimoto, C. Perot, R. Pieters, D. Reinhardt, J.E. Rubnitz, F.O. Smith, J. Stary, I. Stasevich, S. Strehl, T. Taga, D. Tomizawa, D. Webb (Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands)

1067

NOVEL PROGNOSTICS SUBGROUPS IN CHILDHOOD 11Q23/MLLREARRANGED ACUTE MYELOID LEUKEMIA AS DEFINED BY TRANSLOCATION PARTNERS: A RETROSPECTIVE INTERNATIONAL STUDY
B.V. Balgobind, S.C. Raimondi, J. Harbott, M. Zimmermann, T. Alonzo, A. Auvrignon, H.B. Beverloo, M. Chang, U. Creutzig, M.N. Dworzak, E. Forestier, B. Gibson, H. Hasle, C. Harrison, N.A. Heerema, G.J.L. Kaspers, A. Leszl, N. Litvinko, L. Lo Nigro, A. Morimoto, C. Perot, R. Pieters, D. Reinhardt, J.E. Rubnitz, F.O. Smith, J. Stary, I. Stasevich, S. Strehl, T. Taga, D. Tomizawa, D. Webb (Erasmus MC - Sophia Children's Hospital, Rotterdam, The Netherlands)

08:45 – 09:00

1068	AZACITIDINE (AZA) IMPROVES OVERALL SURVIVAL (OS) IN WHO ACUTE MYELOID LEUKEMIA (AML) IN ELDERLY PATIENTS WITH LOW BONE MARROW BLAST COUNTS P.F. Fenaux, L.R. Silverman, G.J. Mufti, E. Hellström-Lindberg, V. Santini, N. Gattermann, G. Sanz, J.F. Seymour, S.D. Gore, H. Dombret, D. McKenzie, J. Backstrom, C.L. Beach (Hopital Avicenne/Université Paris, Bobigny, France)

09:00 – 09:15

1069	PROGNOSTIC SIGNIFICANCE OF CEBPA MUTATIONS IN A LARGE COHORT OF YOUNGER ADULT PATIENTS WITH AML: IMPACT OF DOUBLE CEBPA MUTATIONS AND THE INTERACTION WITH FLT3 AND NPM1 MUTATIONS C.L. Green, K.K. Koo, R.K. Hills, A.K. Burnett, D.C. Linch, R.E. Gale (UCL Cancer Institute, London, United Kingdom

SIMULTANEOUS SESSION

08:00 – 09:15, Hall 6

NOVEL THERAPEUTICS & DRUG RESISTANCE

Chairs: T Fischer (Universitätsklinikum Magdeburg, Magdeburg, Germany)

08:00 – 08:15

1070	PX-171-006: PHASE IB MULTICENTER DOSE ESCALATION STUDY OF CARFILZOMIB (CFZ) PLUS LENALIDOMIDE (LEN) AND LOWDOSE DEXAMETHASONE (LODEX) IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (MM) -- PRELIMINARY RESULTS M. Wang, A. Gutierrez, R. Niesvizky, B. Bensinger, M. Vallone, A.A. Gutierrez, M. Kauffman (M.D. Anderson Cancer Center, Houston, USA)

08:15 – 08:30

1071	POST TRANSPLANT CONSOLIDATION WITH BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE INDUCES A CLINICALLYSIGNIFICANT SHRINKAGE OF RESIDUAL TUMOR BURDEN MEASURED BY REAL TIME PCR A. Palumbo, F. Cavallo, G. Pagliano, S. Ferrero, D. Drandi, M. Boi, L. Santo, P. Pregno, M. Grasso, A.M. Liberati, T. Caravita, F. Pisani, T. Guglielmelli, V. Callea, A.P. Falcone, R. Passera, M. Boccadoro, M. Ladetto (A.O.U. San Giovanni Battista, Torin, Italy)

1071

POST TRANSPLANT CONSOLIDATION WITH BORTEZOMIB, THALIDOMIDE AND DEXAMETHASONE INDUCES A CLINICALLYSIGNIFICANT SHRINKAGE OF RESIDUAL TUMOR BURDEN MEASURED BY REAL TIME PCR
A. Palumbo, F. Cavallo, G. Pagliano, S. Ferrero, D. Drandi, M. Boi, L. Santo, P. Pregno, M. Grasso, A.M. Liberati, T. Caravita, F. Pisani, T. Guglielmelli, V. Callea, A.P. Falcone, R. Passera, M. Boccadoro, M. Ladetto (A.O.U. San Giovanni Battista, Torin, Italy)

08:30 – 08:45

1072	MECHANISMS OF MSC (MESENCHYMAL STEM/STROMAL CELL) ACCUMULATION AT THE SITES OF TUMORS R. Uchibori, M. Urabe, H. Mizukami, A. Kume, K. Ozawa (Jichi Medical University, SHIMOTSUKE-SHI, Tochigi, Japan)

08:45 – 09:00

1073	FOXO REACTIVATION AS A CONSEQUENCE OF IMATINIB TREATMENT IN CML INDUCES QUIESCENCE IN PH+ PROGENITOR CELLS D. Cilloni, C. Panuzzo, F. Messa, E. Greco, F. Arruga, E. Bracco, R. Bernardoni, S. Carturan, M. Pautasso, E. Messa, M. Pradotto, C. Maffè, I. Iacobucci, T. Kalebic, G. Martinelli, G. Saglio (University of Turin, Turin, Italy)

09:00 – 09:15

1074	PGP - DEPENDENT RESISTANCE TO IMATINIB AT ADVANCED CML IS EXCLUSIVELY DEVELOPED IN AGGRESSIVE MINOR BLAST SUBSET AND CAN BE REVERSED BY PGP MODULATORS H. Galski, M. Simanovsky, S. Berlinsky, A.R. Nagler (Chaim Sheba Medical Center, Tel Hashomer, Israel)

SIMULTANEOUS SESSION

08:00 – 09:15, Hall 9

RED BLOOD CELLS, IRON AND GRANULOCYTES

Chairs: C Beaumont (INSERM, Paris, France)
S L Thein (King's College London School of Medicine, London, United Kingdom)

08:00 – 08:15

1075	NRAMP1 PROMOTES EFFICIENT IRON RECYCLING FOLLOWING ERYTHROPHAGOCYTOSIS IN VIVO S. Soe-Lin, S. Apte, B. Andriopoulos, M. Andrews, M. Schranzhofer, $T. Kahawita, D. Garcia Santos, P. Ponka (McGill University, Montreal, Canada)

08:15 – 08:30

1076	PREVENTION OF CARDIAC IRON ACCUMULATION WITH ONCE DAILY ORAL DEFERASIROX THERAPY IN REGULARLY TRANSFUSED PATIENTS WITH B THALASSAEMIA MAJOR D. Pennell, A. El-Beshlawy, P. Sutcharitchan, M. Elalfy, Y. Aydinok, A. Taher, G. Smith, D. Habr, U. Kriemler-Krahn, A. Hmissi, J.B. Porter (Royal Brompton Hospital, London, United Kingdom)

08:30 – 08:45

1077	RITUXIMAB IN AUTO-IMMUNE HAEMOLYTIC ANAEMIA AND IMMUNE THROMBOCYTOPENIC PURPURA: A BELGIANRETROSPECTIVE MULTICENTRIC STUDY D. Dierickx, G. Verhoef, A. Van Hoof, P. Mineur, A. Roest, A. Triffet, A. Kentos, P. Pierre, D. Boulet, G. Bries, P.Q. Lê, B. Deprijk, H. De Samblanx, M.F. Drese,K. Kargar, C. Vermylen, A. Uyttebroeck, M. Delforge, A. Janssens, C. Keppens, A. Delannoy (University Hospitals Gatshuisberg, Leuven, Belgium)

1077

RITUXIMAB IN AUTO-IMMUNE HAEMOLYTIC ANAEMIA AND IMMUNE THROMBOCYTOPENIC PURPURA: A BELGIANRETROSPECTIVE MULTICENTRIC STUDY
D. Dierickx, G. Verhoef, A. Van Hoof, P. Mineur, A. Roest, A. Triffet, A. Kentos, P. Pierre, D. Boulet, G. Bries, P.Q. Lê, B. Deprijk, H. De Samblanx, M.F. Drese,K. Kargar, C. Vermylen, A. Uyttebroeck, M. Delforge, A. Janssens, C. Keppens, A. Delannoy (University Hospitals Gatshuisberg, Leuven, Belgium)

08:45 – 09:00

1078	INVOLVEMENT OF MATRIX METALLOPROTEINASES AND CXC CHEMOKINES IN LPS-INDUCED AIRWAY INFLAMMATION IN SICKLE MICE C. Franco-Penteado, M.A.F. Corat, C. Lanaro, D.M. Albuquerque, A.P. Gimenes, L.A.C. Passos, F.F. Costa (Unicamp, Campinas, Brazil)

09:00 – 09:15

1079	PROLONGED ADMINISTRATION OF HYDROXYUREA REDUCES MORBIDITY AND MORTALITY IN ADULT PATIENTS WITH SICKLE-CELL SYNDROMES: FINAL ANALYSIS OF A 17-YEAR, SINGLE CENTER, TRIAL E. Voskaridou, A. Bilalis, D. Christoulas, K. Varvagiannis, K. Sinopoulou, A. Mpalassopoulou, E. Plata, D. Loukopoulos, E. Terpos (Thalassemia Center, Laikon General Hospital, Athens, Greece)

SIMULTANEOUS SESSION

10:30 – 11:45, Hall 2

AGGRESSIVE NON-HODGKIN CLINICAL

Chairs: R Pytlik (Charles University, Prague, Czech Republic) D Rossi (Az. Ospedale Maggiore della Carità, Novara, Italy)

10:30 – 10:45

1080	SEX-SPECIFIC EFFECTS OF RITUXIMAB ON TREATMENT OUTCOME OF ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELLLYMPHOMA: A RETROSPECTIVE ANALYSIS OF THE RICOVER-60 TRIAL OF THE GERMAN HIGH-GRADE NON-HODGKIN LYMPHOMA STUDY GROUP (DSHNHL) N. Murawski, J. Schubert, S. Zeynalova, V. Poeschel, P. Borchmann, A.D. Ho, C. Nickenig, S. Wessendorf, B. Metzner, M. Loeffler, M. Pfreundschuh (DSHNHL, Homburg/Saar, Germany)

1080

SEX-SPECIFIC EFFECTS OF RITUXIMAB ON TREATMENT OUTCOME OF ELDERLY PATIENTS WITH DIFFUSE LARGE B-CELLLYMPHOMA: A RETROSPECTIVE ANALYSIS OF THE RICOVER-60 TRIAL OF THE GERMAN HIGH-GRADE NON-HODGKIN LYMPHOMA STUDY GROUP (DSHNHL)
N. Murawski, J. Schubert, S. Zeynalova, V. Poeschel, P. Borchmann, A.D. Ho, C. Nickenig, S. Wessendorf, B. Metzner, M. Loeffler, M. Pfreundschuh (DSHNHL, Homburg/Saar, Germany)

10:45 – 11:00

1081	A PHASE II TRIAL OF THE ORAL MTOR INHIBITOR EVEROLIMUS IN RELAPSED NON-HODGKIN LYMPHOMA (NHL) AND HODGKIN DISEASE (HD) E. Witzig, T. Habermann, C. Reeder, I. Micallef, S. Ansell, L. Porrata, P. Johnston, B. LaPlant, B. Kabat, C. Zent, S. Zeldenrust, D. Inwards, J. Colgan, T. Call, S. Markovic, H. Tun (Mayo Clinic, Rochester, USA

11:00 – 11:15

1082	DOSE-DENSE INDUCTION FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) LEADS TO SUSTAINED REMISSIONS IN A LARGE FRACTION OF PATIENTS WITH PREVIOUSLY UNTREATEDPERIPHERAL T-CELL LYMPHOMAS (PTCLS) - OVERALL ANDSUBTYPE-SPECIFIC RESULTS OF A PHASE II STUDY FROM THE NORDIC LYMPHOMA GROUP F. D’Amore, T. Relander, G.F. Lauritzen, E. Jantunen, H. Hagberg, H. Anderson, E. Cavallin-Ståhl, H. Holte, A. Østerborg, M. Merup, P. Brown, O. Kuittinen, M. Erlanson, R. Telhaug, O. Gadeberg, C. Sundström, J. Delabie, E. Ralfkiaer, M. Vornanen, C.B. Jensen (Aarhus University Hospital, Aarhus, Denmark)

1082

DOSE-DENSE INDUCTION FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANT (ASCT) LEADS TO SUSTAINED REMISSIONS IN A LARGE FRACTION OF PATIENTS WITH PREVIOUSLY UNTREATEDPERIPHERAL T-CELL LYMPHOMAS (PTCLS) - OVERALL ANDSUBTYPE-SPECIFIC RESULTS OF A PHASE II STUDY FROM THE NORDIC LYMPHOMA GROUP
F. D’Amore, T. Relander, G.F. Lauritzen, E. Jantunen, H. Hagberg, H. Anderson, E. Cavallin-Ståhl, H. Holte, A. Østerborg, M. Merup, P. Brown, O. Kuittinen, M. Erlanson, R. Telhaug, O. Gadeberg, C. Sundström, J. Delabie, E. Ralfkiaer, M. Vornanen, C.B. Jensen (Aarhus University Hospital, Aarhus, Denmark)

11:15 – 11:30

1083	8X BEACOPPESC COMPARED TO 4X BEACOPPESC FOLLOWED BY 4X BEACOPPBASE WITH OUR WITHOUT RADIOTHERAPY FOR ADVANCED STAGE HODGKIN LYMPHOMA PATIENTS: FINAL ANALYSIS OF THE HD12 TRIAL OF THE GERMAN HODGKIN STUDY GROUP P. Borchmann, H. Haverkamp, R.-P. Mueller, H.-T. Eich, H.K. Mueller- Hermelink, T. Cerny, J. Markova, A.D. Ho, L. Kanz, R. Greil, W. Hiddemann, A. Engert, V. Diehl (Internal Medicine I, Cologne, Germany)

1083

8X BEACOPPESC COMPARED TO 4X BEACOPPESC FOLLOWED BY 4X BEACOPPBASE WITH OUR WITHOUT RADIOTHERAPY FOR ADVANCED STAGE HODGKIN LYMPHOMA PATIENTS: FINAL ANALYSIS OF THE HD12 TRIAL OF THE GERMAN HODGKIN STUDY GROUP
P. Borchmann, H. Haverkamp, R.-P. Mueller, H.-T. Eich, H.K. Mueller- Hermelink, T. Cerny, J. Markova, A.D. Ho, L. Kanz, R. Greil, W. Hiddemann, A. Engert, V. Diehl (Internal Medicine I, Cologne, Germany)

11:30 – 11:45

1084	A PROSPECTIVELY RANDOMIZED PLACEBO-CONTROLLED TRIAL OF EPOETIN-A IN PATIENTS WITH ADVANCED-STAGE HODGKIN LYMPHOMA: FINAL ANALYSIS OF THE GHSG HD15-EPO TRIAL M. Engert, H. Haverkamp, P. Borchmann, A. Josting, M. Fuchs, V. Diehl (Internal Medicine I, Cologne, Germany)

SIMULTANEOUS SESSION

10:30 – 11:45, Hall 15.2

CHRONIC MYELOID LEUKEMIA - CLINICAL II

Chairs: M Müller (Medizinische Universitätsklinik, Mannheim, Germany)
F Guilhot (CHRU La Miletrie, Poitiers, France)

10:30 – 10:45

1090	NILOTINIB 800 MG DAILY IN EARLY CHRONIC PHASE CHRONICMYELOID LEUKEMIA: 12-MONTHS RESULTS OF A PHASE 2 TRIAL OF THE GIMEMA CML WORKING PARTY G. Rosti, F. Castagnetti, M. Breccia, A. Poerio, G. Gugliotta, L. Levato, F. Palandri, A. Capucci, M. Tiribelli, F. Stagno, G. Marzocchi, S. Luatti, M. Amabile, A. Zaccaria, G. Alimena, F. Pane, G. Martinelli, G. Saglio, M. Baccarani (Department of Hematology and Oncological, Bologna, Italy)

1090

NILOTINIB 800 MG DAILY IN EARLY CHRONIC PHASE CHRONICMYELOID LEUKEMIA: 12-MONTHS RESULTS OF A PHASE 2 TRIAL OF THE GIMEMA CML WORKING PARTY
G. Rosti, F. Castagnetti, M. Breccia, A. Poerio, G. Gugliotta, L. Levato, F. Palandri, A. Capucci, M. Tiribelli, F. Stagno, G. Marzocchi, S. Luatti, M. Amabile, A. Zaccaria, G. Alimena, F. Pane, G. Martinelli, G. Saglio, M. Baccarani (Department of Hematology and Oncological, Bologna, Italy)

10:45 – 11:00

1091	DASATINIB 100 MG ONCE DAILY FOR CHRONIC PHASE CHRONIC MYELOID LEUKEMIA (CML-CP) FOLLOWING IMATINIB FAILURE: LONG-TERM FOLLOW-UP FROM STUDY CA180-034 A. Hochhaus, D.W. Kim, H.M. Kantarjian, P. Rousselot, P. Dorlhiac-Llacer, J. Milone, N.P. Shah, Y. Matloub, A. Lambert, R.M. Stone (Universitätsmedizin Mannheim, Mannheim, Germany)

11:00 – 11:15

1092	IMATINIB AND DASATINIB TREATMENT RESULTS IN SELECTION OF A POPULATION OF QUIESCENT LEUKEMIC STEM CELLSSHOWING CROSS-RESISTANCE TO CELLULAR IMMUNOTHERAPEUTIC INTERVENTIONS I. Jedema, L. van Dreunen, R. Willemze, J.H.F. Falkenburg (Leiden University Medical Center, Leiden, The Netherlands)

11:15 – 11:30

1093	MOLECULAR RESPONSES OF THE SPIRIT PHASE III TRIAL OF THE FRENCH CML GROUP COMPARING IMATINIB (IM) 400 MG TO HIGHER DOSE IMATINIB OR COMBINATION WITH INTERFERONOR CYTARABINE FOR THE TREATMENT OF NEWLY DIAGNOSED CHRONIC PHASE (CP) CHRONIC MYELOID LEUKAEMIA (CML) PATIENTS (PTS) P. Rousselot, C. Preudhomme, J. Guilhot, V. Dubruille, T. Lamy, M. Delain, H. Tilly, P. Cony-Makhoul, C. Allard, H. Jardel, S. Cheze, F.X. Mahon, F. Guilhot (Centre Hospitalier de Versailles, Versailles, France)

1093

MOLECULAR RESPONSES OF THE SPIRIT PHASE III TRIAL OF THE FRENCH CML GROUP COMPARING IMATINIB (IM) 400 MG TO HIGHER DOSE IMATINIB OR COMBINATION WITH INTERFERONOR CYTARABINE FOR THE TREATMENT OF NEWLY DIAGNOSED CHRONIC PHASE (CP) CHRONIC MYELOID LEUKAEMIA (CML) PATIENTS (PTS)
P. Rousselot, C. Preudhomme, J. Guilhot, V. Dubruille, T. Lamy, M. Delain, H. Tilly, P. Cony-Makhoul, C. Allard, H. Jardel, S. Cheze, F.X. Mahon, F. Guilhot (Centre Hospitalier de Versailles, Versailles, France)

11:30 – 11:45

1094	EARLY MOLECULAR RESPONSE TO FIRST LINE IMATINIB THERAPY IS PREDICTIVE FOR LONG TERM PFS AND EFS IN CP-CML - AN INTERIM ANALYSIS OF THE RANDOMIZED GERMAN CML STUDY IV M.C. Müller, B. Hanfstein, P. Erben, S. Schnittger, S. Saussele, A. Leitner, N. Pletsch, S. Shazi, M. Lauseker, M. Pfirrmann, G. Ehninger, T. Fischer, J. Hasford, D.K. Hossfeld, H.J. Kolb, S.W. Krause, C. Nerl, H. Pralle,A. Gratwohl, A. Tobler, R. Hehlmann, A. Hochhaus, A. German CML Study Group (Universitaetsmedizin Mannheim, Mannheim, Germany)

1094

EARLY MOLECULAR RESPONSE TO FIRST LINE IMATINIB THERAPY IS PREDICTIVE FOR LONG TERM PFS AND EFS IN CP-CML - AN INTERIM ANALYSIS OF THE RANDOMIZED GERMAN CML STUDY IV
M.C. Müller, B. Hanfstein, P. Erben, S. Schnittger, S. Saussele, A. Leitner, N. Pletsch, S. Shazi, M. Lauseker, M. Pfirrmann, G. Ehninger, T. Fischer, J. Hasford, D.K. Hossfeld, H.J. Kolb, S.W. Krause, C. Nerl, H. Pralle,A. Gratwohl, A. Tobler, R. Hehlmann, A. Hochhaus, A. German CML Study Group (Universitaetsmedizin Mannheim, Mannheim, Germany)

SIMULTANEOUS SESSION

10:30 – 11:45, Hall 2 .1

INFECTIOUS DISEASES, SUPPORTIVE CARE

Chairs: To be announced

10:30 – 10:45

1095	RECOMBINANT ACTIVATED FACTOR VII FOR BLEEDING IN THE SETTING OF MALIGNANCY AND HEMATOPOIETIC STEM CELL TRANSPLANTATION. N. Polizzotto, E. Phillips, F. Cole-Sinclair, S. Dunkley, M. Wood, P. Cameron (Australian Red Cross Blood Service, Melbourne, Australia)

10:45 – 11:00

1096

INCIDENCE OF FEBRILE EPISODES DURING STEM CELLS MOBILIZATION AFTER HIGH DOSE CYCLOPHOSPHAMIDE CHEMOTHERAPY AND G-CSF (FILGRASTIM OR LENOGRASTIM) ADMINISTRATION IN MULTIPLE MYELOMA PATIENTS: STUDY UPDATE
E. Orciuolo, G. Buda, E. Marturano, E. Mauro, D. Pastore, N. Di Renzo, P. Della Cioppa, G. Pietrantuono, C. Cangialosi, M.P. Petrilli, M. Brunori, G. Irrera, B. Bartolozzi, M. Petrini (University of Pisa, Pisa, Italy)

11:00 – 11:15

1097

ENZYME LINKED IMMUNOSPOT (ELISPOT) ASSAY FOR THE DIAGNOSIS OF INVASIVE ASPERGILLOSIS IN HIGH RISK PATIENTS
L. Potenza, P. Barozzi, D. Vallerini, J. Maertens, A. Candoni, G. Riva, E. Zanetti, C. Quadrelli, R. Bosco, M. Morselli, F. Forghieri, M. Maccaferri, L. Pedrazzi, A. Bonini, R. D'Amico, A. Donelli, M. Codeluppi, G. Rossi, F. Ciceri, P. Comoli, F. Narni, G. Torelli, M. Luppi (University of Modena and Reggio Emilia, Modena, Italy)

11:15 – 11:30

1098	MYELOABLATIVE CONDITIONING PREDISPOSES FOR TOXOPLASMA GONDII REACTIVATION AFTER ALLOGENEIC STEM CELL TRANSPLANTATION S. Meers, K. Lagrou, M. Delforge, T. Devos, D. Dierickx, A. Janssens, G. Verhoef, J. Maertens (University Hospital Leuven, Leuven, Belgium)

11:30 – 11:45

1099

PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY FOLLOWING RITUXIMAB THERAPY IN HIV NEGATIVE PATIENTS:A REPORT OF 56 CASES FROM THE RESEARCH ON ADVERSE DRUG EVENT AND REPORTS (RADAR) PROJECT
D. Focosi, K. Carson, A. Evens, E. Richey, T. Habermann, J. Seymour, J Laubach, S. Bawn, L. Gordon, J. Winter, J. Vose, A. Zelenetz, R. Mamtani, D. Raisch, G. Dorshimer, S. Rosen, K. Muro, N. Gottardi-Littell, R. Talley, O. Sartor, D. Green, E. Major, C. Bennett, M. Petrini (University of Pisa, Pisa, Italy)

SIMULTANEOUS SESSION

10:30 – 11:45, Hall 7

ACUTE LYMPHOBLASTIC LEUKEMIA - CLINICAL II

H Dombret (Hôpital Saint-Louis, Paris, France)
A Ferrando (Columbia University, New York, USA)

10:30 – 10:45

1100

PEG-ASPARAGINASE IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): EFFICACY AND FEASIBILITY ANALYSIS WITH FOCUS ON LIVER TOXICITY IN THE GERMAN MULTICENTER STUDY GROUP FOR ADULT ALL (GMALL) STUDY 07/2003
N Gökbuget, A. Baumann, J. Beck, J. Boos, M. Brueggemann, H Diedrich, A. Hüttmann, L. Leimer, T. Lipp, R. Naumann, M. Mohren, A. Reichle, K. Schäfer-Eckart, M. Schmalzing, M. Schmid, N. Schmitz, T. Therwey, D Hoelzer (Goethe University, Frankfurt, Germany)

10:45 – 11:00

1101	MONITORING OF MINIMAL RESIDUAL DISEASE IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA PATIENTS WITHOUT KNOWNGENETIC ABNORMALITIES: IMPACT ON PROGNOSIS IN THE GIMEMA LAL-0904 PROTOCOL R. Foa, On behalf of the GIMEMA Acute Leukemia Working Party (University of Rome “Sapienza”, Rome, Italy)

11:00 – 11:15

1102	PROGNOSTIC IMPLICATIONS OF THE WILMS TUMOR (WT1) GENE MRNA EXPRESSION IN ADULT ACUTE T-LYMPHOBLASTIC LEUKEMIA S. Heesch, N. Goekbuget, A. Stroux, J. Ortiz Tanchez, C. Schlee, T. Burmeister, S. Schwartz, O. Blau, U. Keilholz, A. Busse, D. Hoelzer, W.-K. Hofmann, E. Thiel, C.D. Baldus (Charité, Berlin, Germany)

11:15 – 11:30

1103

GOOD GENERAL MEDICAL CONDITION IN LONG TERM SURVIVORS OF ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) BUT MOREHEALTH IMPAIRMENT IN OLDER PATIENTS AND PATIENTS AFTER STEM CELL TRANSPLANTATION (SCT): RESULTS OF A SYSTEMATIC ANALYSIS OF GMALL STUDIES
N Gökbuget, K Ihrig, CM Hartog, A Hellenbrecht, H Serve, H Diedrich, E Lange, A Schloen, P La Rosee, R Stuhlmann, D Oruzio, D Hoelzer (Goethe University, Frankfurt, Germany)

11:30 – 11:45

1104

A RANDOMISED PHASE II STUDY OF PEGYLATED LIPOSOMAL DOXORUBICINE IN ELDERLY PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): THE GRAALL-SA1 STUDY
M. Hunault-Berger, T. Leguay, X. Thomas, O. Legrand, F. Huguet, F. Witz, P. Chevallier, M. Escoffre-Barbe, L. Legros, P. Turlure, F. Larosa, J.Y. Cahn, O. Reman, P. Rousselot, A. Delannoy, N. Dhedin, M. Pochitaloff, M.C. Bene, N. Ifrah, H. Dombret (CHU, Angers, France)

SIMULTANEOUS SESSION

10:30 – 11:45, Hall 14.2

ACUTE MYELOID LEUKEMIA - BIOLOGY II

Chairs: C Buske (Klinikum Grosshadern, München, Germany) B Falini (Institute of Haematology, Perugia, Italy)

10:30 – 10:45

1105	IDENTIFICATION OF NOVEL MUTATIONS IN ACUTE MYELOID LEUKEMIA USING WHOLE TRANSCRIPTOME SEQUENCING P.A. Greif, A. Benet-Pages, S. Eck, H. Popp, A. Dufour, A. Vetter, T. Meitinger, T.M. Strom, S.K. Bohlander (Clinical Cooperative Group Leukemia / Helmholtz Zentrum München, Munich, Germany)

10:45 – 11:00

1106	SETBP1 OVEREXPRESSION IS A NOVEL LEUKEMOGENICMECHANISM THAT PREDICTS ADVERSE OUTCOME IN ELDERLY PATIENTS WITH ACUTE MYELOID LEUKEMIA I. Cristobal, F.J. Blanco, L. García-Ortí, N. Marcotegui, C. Vicente, J. Rifon, P. Aranaz, F.J. Novo, E. Bandres, M.J. Calasanz, C. Bernabeu, M.D. Odero (CIMA, University of Navarra, Pamplona, Spain)

11:00 – 11:15

1107	STUDYING THE ROLE OF PIM KINASES IN FLT3-ITD-INDUCED LEUKEMIA REVEALED PIM1 AS REGULATOR OF CXCL12/CXCR4- MEDIATED HOMING AND MIGRATION L. Brault, R. Grundler, C. Gasser, A.N. Bullock, S. Ehret, A. Spoo, C. Dierks, A. Biondi, S. Knapp, J. Duyster, J. Schwaller (University Hospital Basel, Basel, Switzerland)

11:15 – 11:30

1108	EVIDENCE FOR CD34+ HEMATOPOIETIC PROGENITOR CELL INVOLVEMENT IN ACUTE MYELOID LEUKEMIA WITH NPM1 GENE MUTATION: IMPLICATIONS FOR THE CELL OF ORIGIN M.P. Martelli, V. Pettirossi, E. Bonifacio, N. Manes, D. Cecchini, I. Gionfriddo, A. Liso, M. Delia, L. Giunchi, R. Rossi, R. Pacini, G. Specchia, M.F. Martelli, B. Falini (Hematology, University of Perugia, Perugia, Italy)

11:30 – 11:45

1109	PROTEIN SYNTHESIS ESCAPES MTORC1 CONTROL AND CONSTITUTES A PROMISING THERAPEUTIC TARGET IN ACUTE MYELOID LEUKEMIA J.T. Tamburini, A.S.G. Green, V.B. Bardet, N.C. Chapuis, S.P. Park, L.W. Willems, M.U. Uzunov, N.I. Ifrah, F.D. Dreyfus, C.L. Lacombe, P.M. Mayeux, D.B. Bouscary (Institut Cochin, Paris, France)

SIMULTANEOUS SESSION

10:30 – 12:00, Hall 4/5

ANEMIA, APLASTIC ANEMIA - PNH, RED BLOOD CELLS AND IRON

Chairs: L Malcovati (University of Pavia & Fondazione IRCCS Policlinico San Matteo, Pavia, Italy)

10:30 – 10:45

1110	ECULIZUMAB REDUCES PULMONARY HYPERTENSION THROUGH INHIBITION OF HAEMOLYSIS-ASSOCIATED NITRIC OXIDE CONSUMPTION IN PATIENTS WITH PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA A. Hill, R. Rother, X. Wang, R. Sapsford, P. Collinson, D. Gaze, S. Morris, A. Scally, K. Quinn-Senger, S. Richards, M. Bessler, R. Kelly, P. Hillmen, M. Galdwin (Bradford Royal Infirmary, Bradford, United Kingdom)

10:45 – 11:00

1111	UNRELATED CORD BLOOD TRANSPLANTATION FOR ACQUIRED BONE MARROW FAILURE SYNDROMES: A RETROSPECTIVE EUROCORD AND EMBT SEVERE APLASTIC ANAEMIA WORKING PARTY ANALYSIS D. Purtill (Eurocord, Paris Cedex, France)

11:00 – 11:15

1112	COMPARISON BETWEEN LYMPHOGLOBULINE- AND THYMOGLOBULINE-BASED IMMUNOSUPPRESSIVE THERAPY ASFIRST-LINE TREATMENT FOR PATIENTS WITH APLASTIC ANEMIA C. Vallejo, P. Montesinos, A. Rosell, S. Brunet, E. Pérez, J. Petit, J. Sevilla, A. Martín, R. Arranz, J. Serna, I. Espigado (University Central Hospital of Asturias, Oveido (Asturias), Spain)

11:15 – 11:30

1113	CONDITIONAL INDUCTION OF MKK6-P38 MAPK SIGNALLING IN GRANULOCYTES INDUCES PHENOTYPIC CHANGES TO MONOCYTE-LIKE CELLS R. Köffel, A. Jörgl, A. Meshcheryakova, M.B. Fischer, C. Scheinecker, H. Strobl (Institute of Immunology, Vienna, Austria)

11:30 – 11:45

1114	THE -509C/T POLYMORPHISM OF TRANSFORMING GROWTH FACTOR-B1 IS ASSOCIATED WITH INCREASED RISK FOR DEVELOPMENT OF CHRONIC IDIOPATHIC NEUTROPENIA D.G. Eliopoulos, I. Mavroudi, C. Pontikoglou, E. Stavroulaki, K. Pyrovolaki,M. Spanoudakis, M. Psyllaki, G. Goulielmos, H.A. Papadaki (University of Crete School of Medicine, Heraklion, Greece)

11:45-12:00

1114a	SUCCESSFUL PREGNANCY OUTCOME IN PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA ON LONG TERM ECULIZUMAB R. Kelly, L.M. Arnold, S.J. Richards, A. Hill, C. Bomken, J. Hanley, J. Beauchamp, G. Khursigara, R.P. Rother, E. Chalmers, A. Fyfe, E. Fitzsimons, R. Nakamura, A. Gaya, B. Rotoli, A. Risitano, J. Schubert, P. Hillmen (St James's University Hospital, Leeds, United Kingdom)

SIMULTANEOUS SESSION

10:30 – 11:45, Hall 6

QUALITY OF LIFE

Chairs: S von Mackensen (Institute of Medical Psychology, Hamburg, Germany)

10:30 – 10:45

1115	WHAT HAS BEEN LEARNED FROM MEASURING PATIENT-REPORTED OUTCOMES IN CLINICAL RESEARCH OF PATIENTS WITH MYELODYSPLASTIC SYNDROMES? A SYSTEMATIC REVIEW FROM 1980 TO 2008 F. Efficace, G. Caocci, M. Vignetti, F. Mandelli, P. Fazi, F. Cottone, G. La Nasa (Gimema, Rome, Italy)

10:45 – 11:00

1116

PAIN AND EMOTIONAL DISTRESS IN LEUKAEMIA PATIENTS SINCE DIAGNOSIS AND DURING ALL PHASES OF THE DISEASE
M. Morselli, M. Luppi, R. Zanin, A. Berti, G. Cacciapaglia, R. Fregni, A. Molitierno, E. Checchi, G. Sasso, V. Ricucci, P. Pelloni, L. Galli, R. Vicini, R. D'Amico, F. Forghieri, L. Potenza, F. Narni, L. Buonaccorso, D. Bolognesi, A. Pietramaggiori, U. Ferrari, F. Artioli, E. Bandieri, C. Ripamonti, G.

11:15 – 11:30

1118	'PAINLESS' BONE MARROW ASPIRATION BY SLOW SUCTIONING DO NOT AFFECT PERIPHERAL BLOOD CONTAMINATION TO THE SPECIMEN: RANDOMIZED PROSPECTIVE CROSSOVER TRIALS Y. Asano-Mori, S.I. Mori, T. Ueki, M. Sakai, T. Yamashita, K. Ohashi, H. Akiyama, H. Sakamaki (Toranomon Hospital, Tokyo, Japa

11:30 – 11:45

1119	RISK FACTORS FOR ATTEMPTED SUICIDE AND SUICIDE FOLLOWING A DIAGNOSIS OF HEMATOLOGICAL MALIGNANCY M. Hultcrantz, T. Svensson, A.R. Derolf, S.Y. Kristinsson, A. Ekbom, F. Granath, M. Björkholm (Karolinska University Hospital, Stockholm, Sweden)

SIMULTANEOUS SESSION

10:30 – 11:45, Hall 9

TRANSFUSION MEDICINE

Chairs: N Mohandas (New York Blood Center, New York, USA)
J Zwaginga (University Medical Centre, Leiden, The Netherlands)

10:30 – 10:45

1120	ANIMAL MODELS FOR THE TWO HYPOTHESES OF TRALI PATHOLOGY M.B. Tamarozzi, S.G. Soares, A. Sá-Nunes, F.P. Saggioro, J.O. Bordin, A.G. Garcia, E.M. Rego (Medical School of Ribeirao Preto - USP, Ribeirao Preto, Brazil)

10:45 – 11:00

1121	AN ACTIVE HEMOVIGILANCE PROGRAM TO CHARACTERIZE THE SAFETY PROFILE OF 16,631 PLATELET COMPONENTS PREPARED WITH PHOTOCHEMICAL PATHOGEN INACTIVATION TREATMENT TRANSFUSED IN ROUTINE CLINICAL PRACTICE J.C. Osselaer, J.P. Cazenave, P. Rasongles, F. Knutson, L. Lin, L. Corash (Blood Transfusion Center, Clin Univ de Mont Godinne, Univ Cath de Louvain, Yvoir, Belgium)

11:00 – 11:15

1122	UNDERSTANDING AND MEETING CLINICAL PLATELETREQUIREMENTS: AN ANALYSIS OF INDICATIONS AND URGENCYOF PLATELET USE FROM THE PROSPECTIVE UTILISATION OF PLATELETS AND PLASMA (PUPPY) STUDY N. Polizzotto, N. Waters, M. Comande, G. Grigoriadis, M. Borosak, D. Jolley (Australian Red Cross Blood Service, Melbourne, Australia)

11:15 – 11:30

1123	A SELF-OPERATING PRETRANSFUSION BLOOD SAMPLING DEVICE FOR ENHANCED TRANSFUSION SAFETY: PROSPECTIVE PHASE II TRIAL IN EMERGENCY CARE M. Notter (Charité, Berlin, Germany)

11:30 – 11:45

1124	EVALUATION OF THE CLINICAL SIGNIFICANCE AND RISK FACTORS FOR INTRA-VENOUS IMMUNE GLOBULIN INDUCED HAEMOLYTIC REACTIONS. R. Kotb, J.A. Boisjoly, P. Beauregard (CHU de Sherbrooke, Sherbrooke, Canada)

[

Print view ]